Sign In
Buy BLFS
$34.64
-0.0200 (-0.0577%)
At Close: Aug 10, 2026
BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Surpass Estimates
06:41pm, Thursday, 06'th Aug 2026
BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to break-even earnings per share a
BioLife Solutions Reports Second Quarter 2026 Financial Results
04:03pm, Thursday, 06'th Aug 2026
Total revenue of $28.5 million, up 21% over Q2 2025 GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65% GAAP net income of $45.1 million, inclusive of a $42.4 million non-cash income ta
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
12:41pm, Thursday, 23'rd Jul 2026
RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach
03:04pm, Wednesday, 22'nd Jul 2026
Repligen NASDAQ: RGEN said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that manageme
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of BioLife Solutions, Inc. (NASDAQ: BLFS)
03:00pm, Wednesday, 22'nd Jul 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of BioLife Solutions, Inc. (NASDAQ: BLFS) PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of BioLife Solutions, Inc. (NASDAQ: BLFS)
02:04pm, Wednesday, 22'nd Jul 2026
NEW YORK, July 22, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and i
Shareholder Alert: Ademi LLP investigates whether BioLife Solutions, Inc. is obtaining a Fair Price for Public Shareholders
12:00pm, Wednesday, 22'nd Jul 2026
Shareholder Alert: Ademi LLP investigates whether BioLife Solutions, Inc. is obtaining a Fair Price for Public Shareholders PR
Shareholder Alert: Ademi LLP investigates whether BioLife Solutions, Inc. is obtaining a Fair Price for Public Shareholders
11:34am, Wednesday, 22'nd Jul 2026
MILWAUKEE, July 22, 2026 /PRNewswire/ -- Ademi LLP is investigating BioLife (NASDAQ: BLFS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction wit
BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLife Solutions, Inc. is Obtaining a Fair Price for its Shareholders
10:00am, Wednesday, 22'nd Jul 2026
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of BioLife Solutions, Inc. (NASDAQ: BLFS) to Repligen Corporation for $11.25 per share
Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition
09:41am, Wednesday, 22'nd Jul 2026
Life sciences company Repligen Corporation (NASDAQ:RGEN) on Wednesday agreed to acquire cell processing developer BioLife Solutions Inc. (NASDAQ:BLFS) for an enterprise value of approximately $1.5 bil
BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLife Solutions, Inc. is Obtaining a Fair Price for its Shareholders
09:10am, Wednesday, 22'nd Jul 2026
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of BioLife Solutions, Inc. (NASDAQ: BLFS) to Repligen Corporation for $11.25 per share in cash and 0
Repligen to buy cell therapy maker BioLife in $1.5 billion deal
06:13am, Wednesday, 22'nd Jul 2026
Repligen Corp said on Wednesday it would buy BioLife Solutions in a cash-and-stock deal valued at about $1.5 billion, to expand the drugmaking equipment provider's presence in the fast-
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
06:00am, Wednesday, 22'nd Jul 2026
Fast-tracks Repligen's leadership and customer solution offering in high-growth cell therapy market by adding BioLife's differentiated, high-margin recurring revenue business
BioLife Solutions Inc (BLFS) Stock Up 3.1% and Still Undervalued -- GF Score: 73/100
09:07pm, Thursday, 28'th May 2026
On May 28, 2026, BioLife Solutions Inc (BLFS) shares rose 3.1% to a current price of $25.25. This movement comes amid a 52-week range that sees a high of $29.62
